Predict your next investment

Corporation
HEALTHCARE | Drug Development
bukwang.co.kr

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Partners & Customers

5

About Bukwang Pharmaceutical

Bukwang Pharmaceuticals is focused on developing therapeutics to enhance global health. For over 50 years, Bukwang has kept a clean and robust track record, which forms the basis for the trust that its employees and shareholders hold in Bukwang. The company's sales structure has its primary roots on original, prescription products and is supported by a wide array of over-the-counter drugs and personal hygiene amenities. Bukwang's products are fruits of extensive cooperation with partners in Germany, France, Spain, and Japan.

Bukwang Pharmaceutical Headquarter Location

7, Sangdo-ro Dongjak-gu

Seoul, 06955,

South Korea

+82 (0)2 828 8114

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Bukwang Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bukwang Pharmaceutical Rank

Latest Bukwang Pharmaceutical News

Bukwang Announces Completion of SOL-804’s Phase 1 clinical trial

Mar 17, 2022

Bukwang Announces Completion of SOL-804’s Phase 1 clinical trial 기사공유하기 Kim Min-jee Headquarters of Bukwang Pharmaceutical Bukwang Pharmaceutical announced the completion of SOL-804’s phase 1 clinical trial through Dyna therapeutics, a subsidiary company of Bukwang. This study is for finding the right dosage of the drug and conducted in Seoul National Univ. hospital with 40 patients. It was compared to Zytiga as a control drug in the safety, tolerance, and pharmacodynamics characteristics and was conducted in a way of randomized, crossed, and single dose administered. SOL-804 is an improved and proprietary formulated version of a currently available drug for the treatment of metastatic castration-resistant prostate cancer. It is expected to improve the convenience and drug compliance of the patients. Buwang is going to conduct a clinical trial for the permission after dose finding with this result of SOL-804’s phase 1 study. This is a strategy for the rapid permission and Bukwang will secure the advantage compared to the control drug(Zytiga) through conducting another clinical trial which finds out if it would improve the problem of taking steroids. The global market size of prostate cancer has been getting bigger and passed over 12 trillion dollars in 2019. It will reach 23 trillion dollars in 2027. The subsidiary of Bukwang, Dyna Therapeutics (“Dyna”) registered a composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to the U.S. The patent is also approved in Japan, Eurasia, Europe, Australia, Mexico, and Singapore, etc. Bukwang has been also improving new immuno-oncology therapeutics for global markets targeting the AhR pathway through JaguAhR Therapeutics, a joint venture between Bukwang and ASLAN Pharmaceuticals. Bukwang is also focusing on  CAR-T treatment  with another bio venture, ImmPACT Bio USA Inc. It is developing a novel set of engineered T-cell therapeutics that target loss of genes in solid tumors. Bukwang said, “They secured funding to improve anti-cancer medicine which requires great expense through joint management with OCI.” 저작권자 © Korea IT Times 무단전재 및 재배포 금지

Bukwang Pharmaceutical Investments

6 Investments

Bukwang Pharmaceutical has made 6 investments. Their latest investment was in ImmPACT Bio as part of their Series B on January 1, 2022.

CBI Logo

Bukwang Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/20/2022

Series B

ImmPACT Bio

$111M

No

15

8/5/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/13/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/29/2019

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

5/6/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/20/2022

8/5/2020

11/13/2019

5/29/2019

5/6/2016

Round

Series B

Series A

Series A

Corporate Minority

Series B

Company

ImmPACT Bio

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$111M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

15

10

10

10

10

Bukwang Pharmaceutical Portfolio Exits

1 Portfolio Exit

Bukwang Pharmaceutical has 1 portfolio exit. Their latest portfolio exit was Acer Therapeutics on September 20, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/20/2017

Reverse Merger

$99M

3

Date

9/20/2017

Exit

Reverse Merger

Companies

Valuation

$99M

Acquirer

Sources

3

Bukwang Pharmaceutical Acquisitions

1 Acquisition

Bukwang Pharmaceutical acquired 1 company. Their latest acquisition was Contera Pharma on September 29, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/29/2014

Series B

$99M

$45.03M

Acquired

2

Date

9/29/2014

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$45.03M

Note

Acquired

Sources

2

Bukwang Pharmaceutical Partners & Customers

5 Partners and customers

Bukwang Pharmaceutical has 5 strategic partners and customers. Bukwang Pharmaceutical recently partnered with ASLAN Pharmaceuticals on September 9, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

9/30/2019

Partner

Singapore

ASLAN Pharmaceuticals and Bukwang Pharmaceutical establish a joint venture, JAGUAHR Therapeutics, to develop novel immuno-oncology therapies - ASLAN Pharmaceuticals

ASLAN Pharmaceuticals and Bukwang Pharmaceutical establish a joint venture , JAGUAHR Therapeutics , to develop novel immuno-oncology therapies .

2

7/3/2019

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

10/16/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

5/31/2018

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

12/4/2013

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

9/30/2019

7/3/2019

10/16/2018

5/31/2018

12/4/2013

Type

Partner

Partner

Partner

Partner

Licensor

Business Partner

Country

Singapore

United Kingdom

United States

South Korea

United States

News Snippet

ASLAN Pharmaceuticals and Bukwang Pharmaceutical establish a joint venture, JAGUAHR Therapeutics, to develop novel immuno-oncology therapies - ASLAN Pharmaceuticals

ASLAN Pharmaceuticals and Bukwang Pharmaceutical establish a joint venture , JAGUAHR Therapeutics , to develop novel immuno-oncology therapies .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.